Bosutinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of certain types of cancer, specifically chronic myeloid leukemia (CML). It targets and inhibits the BCR-ABL fusion protein, which is produced by the Philadelphia chromosome abnormality commonly found in CML patients.
